research
PCF has helped bring more medicines into the research pipeline.
Alternative Endpoints: Results that Potentially Accelerate Phase 3 Clinical Trials in Metastatic Hormone-Sensitive Prostate Cancer
Clinical trials can bring life-extending and potentially curative new treatments to patients with cancer. They play a vital role in determining the safety and efficacy of investigational treatments, generating data which the FDA requires for making decisions on whether a new therapy can be approved and enter widespread clinical practice.. Read More
Young Investigator Award-Class of 2016
The PCF Young Investigator Award-Class of 2016 recipients are: 2016 Elliot Abramowitz–PCF Young Investigator Award Rohit Bose, MD, PhD Memorial Sloan Kettering Cancer Center Mentor: Charles Sawyers, MD Proposal Title: Epigenetic Sensitization of Enzalutamide Response Description The androgen receptor (AR) is the primary driver of prostate cancer, and targeting AR is. Read More
Creativity Awards Recipients 2011
A rigorous peer review process vetted the 14 selected projects from a field of more than 200 applications representing leading institutions in 11 countries. Historically, 70 percent of such PCF awards have gone on to attract additional multi-year funding from PCF and other sources. These two-year awards are designed to support new. Read More
Creativity Awards Recipients 2009
Following a rigorous peer review process, PCF selected 10 Creativity Award recipients from more than 300 applications representing 105 institutions in 11 countries. The projects represent a range of research areas, from biomarkers for earlier and more precise detection and treatment to the development of new, nano-enabled therapeutics for metastases.. Read More
Challenge Awards-Class of 2016
2016-2018 Movember Foundation-PCF Challenge Award ($1 Million) Principal Investigators: Andrew Hsieh, MD (Fred Hutchinson Cancer Research Center), Yu Chen, MD, PhD (Memorial Sloan Kettering Cancer Center), Brett Carver, MD, PhD (Memorial Sloan Kettering Cancer Center) Co-investigators: Peter Nelson, MD (Fred Hutchinson Cancer Research Center), Dana Rathkopf, MD (Memorial Sloan Kettering. Read More
New Clinical Trial Methods Accelerate Research and Development
Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive. Read More
Progress Report: Andrea Harzstark, MD
Investigator: Andrea Harzstark, MD – Assistant Professor, University of California, San Francisco Tobacco and Prostate Cancer Therapy: The Missing Link? Prostate cancer affects one in every six American men; ~25% of those men are smokers. Smoking causes many health risks, including a higher risk for lung cancer. Many of the. Read More
Progress Report: Thomas Guzzo, MD, MPH
Investigator: Thomas Guzzo, MD, MPH – Assistant Professor, University of Pennsylvania Reducing Morbidity from Surgery and Physician Counseling of Treatment Costs Dr. Guzzo has had a very prolific second year as a PCF Young Investigator as evidenced by his publication of ten scientific and clinical reports. His primary research aims. Read More
Progress Report: Steven Frank, MD
Investigator: Steven Frank, MD– Assistant Professor, University of Texas, M.D. Anderson Cancer Center C4 and MRI-based Prostate Brachytherapy Brachytherapy is a form of radiotherapy where a radiation source, called “seeds”, is precisely implanted into the prostate such that emitted radiation will abolish the tumor. Recent technological advances have increased the. Read More
Progress Report: Adam S. Feldman, MD, MPH
Investigator: Adam S. Feldman, MD, MPH–Assistant Professor of Surgery, Massachusetts General Hospital, Harvard School of Medicine Active Surveillance: Identifying When to Treat and When Not to Treat In 2010 nearly 218,000 men will be diagnosed with prostate cancer in the United States. However, ~50% of those men will have low. Read More